IPO Year:
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/17/2025 | $42.00 | Buy | Citigroup |
| 6/10/2025 | $44.00 | Buy | Stifel |
| 6/4/2025 | $42.00 | Overweight | Cantor Fitzgerald |
| 12/30/2024 | $48.00 | Buy | H.C. Wainwright |
| 5/15/2024 | Buy | TD Cowen | |
| 3/14/2024 | $35.00 | Sector Outperform | Scotiabank |
| 1/18/2024 | $30.00 | Buy | Guggenheim |
| 1/16/2024 | $37.00 | Overweight | Piper Sandler |
| 10/30/2023 | $25.00 | Outperform | RBC Capital Mkts |
4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)
4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)
4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)
4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)
4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)
4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)
4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)
4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)
Citigroup initiated coverage of NewAmsterdam Pharma with a rating of Buy and set a new price target of $42.00
Stifel initiated coverage of NewAmsterdam Pharma with a rating of Buy and set a new price target of $44.00
Cantor Fitzgerald initiated coverage of NewAmsterdam Pharma with a rating of Overweight and set a new price target of $42.00
H.C. Wainwright initiated coverage of NewAmsterdam Pharma with a rating of Buy and set a new price target of $48.00
TD Cowen initiated coverage of NewAmsterdam Pharma with a rating of Buy
Scotiabank initiated coverage of NewAmsterdam Pharma with a rating of Sector Outperform and set a new price target of $35.00
Guggenheim initiated coverage of NewAmsterdam Pharma with a rating of Buy and set a new price target of $30.00
Piper Sandler initiated coverage of NewAmsterdam Pharma with a rating of Overweight and set a new price target of $37.00
RBC Capital Mkts initiated coverage of NewAmsterdam Pharma with a rating of Outperform and set a new price target of $25.00